Related Experiment Video
Updated: May 25, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.2K
Hypertension and Atrial Fibrillation: Bridging the Gap Between Mechanisms, Risk, and Therapy
Ibrahim Antoun1,2, Georgia R Layton2,3, Ali Nizam1
1Department of Cardiology, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester LE3 9QP, UK.
Medicina (Kaunas, Lithuania)
|February 26, 2025
Summary
Hypertension significantly increases atrial fibrillation (AF) risk by altering heart structure. Managing blood pressure, especially via renin-angiotensin-aldosterone system (RAAS) blockers, reduces AF incidence and improves treatment outcomes.
Area of Science:
- Cardiology
- Internal Medicine
- Public Health
Background:
- Atrial fibrillation (AF) is a common arrhythmia linked to stroke, heart failure, and mortality.
- Hypertension is a major modifiable risk factor for AF, causing atrial structural and electrical changes.
- These changes include dilation, fibrosis, and pressure overload, increasing AF susceptibility.
Purpose of the Study:
- To review shared mechanisms, risks, and treatments for hypertension and atrial fibrillation.
- To understand how hypertension influences AF development and management.
- To identify effective strategies for mitigating AF in hypertensive patients.
Main Methods:
- Literature search on hypertension and atrial fibrillation.
- Analysis of shared pathophysiological pathways.
- Review of current and emerging treatment strategies.
Main Results:
- The renin-angiotensin-aldosterone system (RAAS) is implicated in atrial remodeling and inflammation, promoting AF.
- Uncontrolled hypertension impairs AF treatments like antiarrhythmic drugs and catheter ablation.
- Blood pressure control, particularly RAAS inhibition, lowers new-onset and recurrent AF risk, improving rhythm control success.
Conclusions:
- Integrated strategies combining blood pressure control, AF screening, and lifestyle changes are crucial.
- Further research is needed on cellular mechanisms, inflammation, genetics, and personalized treatments for hypertension-driven AF.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
568
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
568
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
452
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
452
01:25Antihypertensive Drugs: Direct Renin Inhibitors
469
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
469
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K